Latest news with #Resolutions
Yahoo
22-05-2025
- Business
- Yahoo
Biodexa Pharmaceuticals PLC ('Biodexa' or the 'Company') Notice of General Meeting
May 22, 2025 Biodexa Pharmaceuticals PLC('Biodexa' or the 'Company') Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company's offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 11 June 2025 at 1.00pm was posted to shareholders today. The Board of Directors is proposing four resolutions: Ordinary Resolutions 1. That, subject to and conditional on the passing of Resolution 4, each of the issued ordinary shares of £0.001 each in the capital of the Company be subdivided and redesignated into one ordinary share of £0.00005 each and 19 C deferred shares of £0.00005 each (such C deferred shares having the rights and being subject to the restrictions set out in the articles of association of the Company adopted pursuant to Resolution 4). 2. That the Directors of the Company be generally and unconditionally authorised in accordance with Section 551 of the Companies Act 2006 (the 'Act'), in addition to any existing authorities to allot equity securities to the extent unused, to exercise all powers of the Company to allot shares in the Company or to grant rights to subscribe for or convert any security into shares in the Company up to an aggregate nominal value of £476,954.10, provided that this authority shall expire at the conclusion of the Annual General Meeting of the Company to be held in 2028. Special Resolutions3. That, subject to and conditional upon the passing of Resolution 2, the Directors of the Company be and hereby generally empowered pursuant to Sections 570 of the Act to allot equity securities (within the meaning of Section 560 of the Act) wholly for cash, in addition to any existing authorities to allot equity securities to the extent unused, pursuant to the authority conferred by Resolution 2 as set out in this Notice, as if Section 561 of the Act did not apply to such allotment, provided that this power shall expire at the conclusion of the Annual General Meeting of the Company to be held in 2028. 4. That, subject to and conditional on the passing of Resolution 1, the draft articles of association tabled at the meeting, initialled by the Chairman, and available on the Company's website, and labelled the 'New Articles', be approved and adopted as the new articles of association of the Company in substitution for and to the entire exclusion of the Company's existing articles of association. The purpose of the Resolutions is to lower the par value of the ordinary shares and allow the Company to issue ordinary shares above par value. Neither the number of ordinary shares outstanding nor the number of American Depositary Shares will change as a result of passing of the Resolutions. About Biodexa Pharmaceuticals PLC Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications. eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis. Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent. MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa's headquarters and R&D facility is in Cardiff, UK. For more information visit Forward-Looking StatementsCertain statements in this announcement may constitute 'forward-looking statements' within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management's belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as 'plans', 'expects' or 'does not anticipate', or 'believes', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved.' Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise in to access your portfolio
Libya Review
05-05-2025
- Business
- Libya Review
Libya Warns UK Against Using Frozen Funds
The Libyan Parliament has strongly rejected any attempt by the United Kingdom or other countries to seize or utilise Libya's frozen assets held abroad, calling such actions a 'blatant violation' of international law and United Nations Security Council resolutions. In a statement issued by the Parliamentary Committee for Investigating Libyan Frozen Funds Abroad, lawmakers condemned recent discussions in the UK's House of Lords regarding the possible use of Libyan assets to compensate victims of the Irish Republican Army (IRA). The committee cited UN Security Council Resolutions 1970 and 1973 (2011), which explicitly prohibit tampering with Libyan funds frozen overseas. The UK has previously ruled out using the assets to pay compensation, although it has acknowledged that former Libyan leader Muammar Gaddafi's regime supplied weapons to the IRA during its conflict with Britain. Among these were large quantities of Semtex explosives, reportedly used in several IRA bombings. Committee head Yousef Al-Aqouri warned that any action to appropriate Libyan funds would be seen as 'an unacceptable and unjustified act' and a direct assault on the Libyan people's national resources. He added that Libya reserves the right to take all necessary legal and diplomatic measures to safeguard its financial assets and prevent their misuse. 'This issue is a national priority that cannot be compromised or negotiated,' Aqouri stressed, urging countries hosting Libyan assets to comply with international obligations and respect Libya's sovereignty. The statement concluded with a call for friendly nations to uphold international law and support mutual interests through respectful bilateral relations. Libyan lawmakers warned that failure to do so would damage diplomatic ties and undermine global trust in the international financial system. The frozen assets, valued in the billions, remain a sensitive and politically charged issue amid Libya's ongoing struggle for stability and sovereignty. Tags: Frozen AssetslibyaLibyan parliamentUnited Kingdom
Russia Today
26-03-2025
- Politics
- Russia Today
Taiwan requests more time to move ‘unofficial embassy' in BRICS state
With Taiwan's South African office having been recently downgraded from Taipei Liaison Office (TLO) to Taipei Commercial Office (TCO), the Department of International Relations and Cooperation (DIRCO) has revealed that while the impending relocation of the Taiwan office has been set in stone, Taipei has indicated that this might take longer than expected due to budgetary constraints. The South African government had initially ordered Taiwan to move its Pretoria office to Johannesburg in October 2024, but talks between the countries resulted in a new date of end of March being set. However, with just under a week to go before the deadline, this might not happen as Taiwan and the South African government are still engaged in a possible change of date due to financial implications associated with this relocation. DIRCO spokesperson Chrispin Phiri has indicated that due to the shift in relations between the two countries since the advent of democracy, this name change reflects the current government's position on its relations with Taiwan. 'The name change is the accurate representation of the status of their office... The apartheid government maintained close ties with Taiwan, this relationship shifted after the country's democratic transition in 1994. Since joining the UN in 1994, South Africa has aligned with international consensus and adhered to UN Resolutions, including Resolution 2758 (1971), which recognises the People's Republic of China (PRC) as the sole legitimate representative of China. READ MORE: BRICS state gives Taiwan deadline to move 'unofficial embassy' 'In 1997, South Africa severed diplomatic ties with Taiwan and maintained a non-political, non-diplomatic engagement. In 1998, South Africa formalised its diplomatic relations with the PRC and committed to the One China Policy, which asserts that Taiwan is an inalienable part of China,' Phiri stated. It has been reported that as the deadline looms large over this relocation, Taiwan has formally requested talks to decide on the relocation site, personnel arrangements, and agreement signing details. READ MORE: From Soviet classrooms to presidential palaces: How the USSR educated African leaders 'The location of the Taiwan Liaison Office (TLO) is simply a matter of geography and poses no threat to the Republic of South Africa. Our relationship with Taiwan revolves around trade, rather than political or diplomatic concerns. The Taiwanese Authorities have indicated that they cannot adhere to the relocation deadline for various reasons, including budgetary concerns. The discussions are ongoing, and in the interim, South Africa is following domestic processes to undertake administrative adjustments that appropriately reflect the status of Taiwanese representation in South Africa,' Phiri further stated. DIRCO renamed the 'Taipei Liaison Office' to the 'Taipei Commercial Office' on its website earlier this month, saying the relocation will not hinder but enhance economic ties between the two nations. READ MORE: South Africa denies being under Chinese pressure 'The relocation of the TLO presents a unique opportunity that promises to enhance economic and trade relations. Johannesburg, a thriving commercial and financial hub, is ideally positioned to foster productive economic collaborations. 'South Africa is committed to strengthening its non-diplomatic ties with the island, focusing on lucrative areas such as trade, investment, and education. This strategic approach will be facilitated through a non-binding Memorandum of Arrangement with the Taipei Authorities,' Phiri added. First published by IOL
Yahoo
11-03-2025
- Politics
- Yahoo
Trump pledges to 'lead the charge' against Rep. Massie, likens him to Liz Cheney
President Donald Trump lashed out at Rep. Thomas Massie, R-Ky., in a Monday night Truth Social post, declaring that the congressman "SHOULD BE PRIMARIED" and pledging to "lead the charge against him." Trump likened Massie to former Rep. Liz Cheney, of Wyoming, one of the 10 House Republicans who voted to impeach Trump following the Jan. 6, 2021, Capitol riot. "Congressman Thomas Massie, of beautiful Kentucky, is an automatic 'NO' vote on just about everything, despite the fact that he has always voted for Continuing Resolutions in the past. HE SHOULD BE PRIMARIED, and I will lead the charge against him. He's just another GRANDSTANDER, who's too much trouble, and not worth the fight. He reminds me of Liz Chaney(sic) before her historic, record breaking fall (loss!). The people of Kentucky won't stand for it, just watch. DO I HAVE ANY TAKERS???" Trump wrote in the post. Trump-endorsed primary challenger Harriet Hageman handily defeated Cheney in the 2022 Republican primary for Wyoming's at-large Congressional District. Hageman, who went on to win the 2022 general election, was re-elected last year, while former Rep. Cheney, a vociferous Trump critic, supported then-Vice President Kamala Harris in the 2024 presidential election. Massie Says He's A 'No' On Trump-endorsed Government Funding Measure: 'Unless I Get A Lobotomy' As the deadline to prevent an impending partial government shutdown approaches, Massie has indicated that he will vote against the government funding measure that Trump has been urging Republicans to support. Read On The Fox News App "Unless I get a lobotomy Monday that causes me to forget what I've witnessed the past 12 years, I'll be a NO on the CR this week. It amazes me that my colleagues and many of the public fall for the lie that we will fight another day," Massie wrote on X on Sunday. Sen. Mike Lee responded to Trump's attack against Massie by speaking out in support of the congressman. "I have nothing but profound respect for @RepThomasMassie, who has worked harder than perhaps any member of Congress to bring federal spending under control," Lee wrote on X. "He might vote differently on this matter than most, but if he does so he'll have a really good reason," the senator continued. "I'm a huge fan." Trump-backed Plan To Avert Shutdown Heads For House Vote Trump included the broadside against the House Republican maverick in the middle of a post in which he thanked the House Freedom Caucus for supporting the measure. "Thank you to the House Freedom Caucus for just delivering a big blow to the Radical Left Democrats and their desire to raise Taxes and SHUT OUR COUNTRY DOWN! They hate America and all it stands for. That's why they allowed MILLIONS of Criminals to invade our Nation. Sometimes it takes great courage to do the right thing," Trump said in the post, before launching the attack against Massie. After blasting Massie in the post, the president added, "Anyway, thank you again to the House Freedom Caucus for your very important vote. We need to buy some time in order to MAKE AMERICA GREAT AGAIN, GREATER THAN EVER BEFORE. Unite and Win!!!" While Massie has not yet responded to Trump's remarks, in an X post prior to Trump's attack on Monday, the congressman already indicated that he is not intimidated by the prospect of being primaried. "Someone thinks they can control my voting card by threatening my re-election. Guess what? Doesn't work on me. Three times I've had a challenger who tried to be more MAGA than me. None busted 25% because my constituents prefer transparency and principles over blind allegiance," he wrote. Massie and Trump have a rocky history. In 2020, Trump called for the congressman to be booted from the GOP. "Looks like a third rate Grandstander named @RepThomasMassie, a Congressman from, unfortunately, a truly GREAT State, Kentucky, wants to vote against the new Save Our Workers Bill in Congress. He just wants the publicity," Trump declared in a March 2020 tweet. "He can't stop it, only delay, which is both dangerous," Trump wrote in the post, before continuing his thought in another post, "& costly. Workers & small businesses need money now in order to survive. Virus wasn't their fault. It is 'HELL' dealing with the Dems, had to give up some stupid things in order to get the "big picture" done. 90% GREAT! WIN BACK HOUSE, but throw Massie out of Republican Party!" Months later, Massie sailed to a decisive Republican primary victory. Massie And Other Republicans Push 'National Constitutional Carry Act' To Protect Americans' Gun Rights Then, in 2022, Trump did an about-face, endorsing Massie shortly before the congressman earned another resounding GOP primary win. In 2023, Massie endorsed Florida Gov. Ron DeSantis for president before the Sunshine State politician even launched his presidential primary bid. In early 2024, DeSantis dropped out of the race and endorsed Trump. Massie ultimately endorsed Trump less than two weeks before the general article source: Trump pledges to 'lead the charge' against Rep. Massie, likens him to Liz Cheney
